-
May 21, 2013
Roche has one of the best long-term growth profiles in the Big Pharma space
-
May 08, 2013
Amgen really needs the pipeline to come through to support this valuation.
-
February 11, 2013
Recently, Gilead Sciences, Inc. (GILD) completed its acquisition of Canada-based drug development company, YM ...
-
February 05, 2013
Gilead Sciences, Inc.'s (GILD) fourth quarter 2012 earnings (excluding special items but including stock option ...
-
January 29, 2013
We are in the midst of the fourth quarter earnings season and it is once again time to review the players in the ...
-
January 29, 2013
We are in the midst of the fourth quarter earnings season and it is once again time to review the players in the ...
-
January 25, 2013
Investing in biotechnology can be exciting, profitable, and loaded with land mines. For every company that hits the ...
-
January 25, 2013
Gilead Sciences Inc. (GILD) recently initiated the first of two phase III studies on tenofovir alafenamide (TAF). ...
-
January 14, 2013
During the past 10 years, the best hedge funds have consistently produced market-beating returns, driving huge ...
-
January 14, 2013
Gilead Sciences (GILD) recently provided an update regarding its chronic hepatitis C virus (HCV) pipeline. We ...
-
December 18, 2012
Switzerland-based Actelion (ALIOF) recently announced that the US Food and Drug Administration (FDA) accepted its ...
-
December 13, 2012
In a bid to expand its oncology pipeline, biopharmaceutical company Gilead Sciences Inc. (GILD) inked a definitive ...
-
December 11, 2012
Recently, the board of directors at Gilead Sciences Inc. (GILD) authorized a two-for-one stock split. The action, ...
-
December 06, 2012
The pharmaceutical industry is slowly showing signs of recovery from one of the biggest patent cliffs in recent ...
-
December 06, 2012
The pharmaceutical industry is slowly showing signs of recovery from one of the biggest patent cliffs in recent ...
-
December 03, 2012
Good news flowed in at Gilead Sciences Inc. (GILD) from Europe regarding its drug Viread. The European Commission ...
-
November 29, 2012
Gilead Sciences (GILD) recently presented encouraging top-line data from a phase III study (Positron) which ...
-
November 26, 2012
The European Medicines Agency (EMA) recently accepted the Marketing Authorisation Application (MAA) filed by ...
-
November 16, 2012
Gilead Sciences (GILD) recently presented encouraging long-term data on its HIV therapy Stribild from two ongoing ...
-
November 16, 2012
With the election over, many investors assumed that one of the key risk events for U.S. markets was past us. ...
